Phase 3 LITESPARK-012 trial by Merck and Eisai fails to improve survival outcomes in first-line advanced renal cell carcinoma, reinforcing KEYTRUDA plus LENVIMA standard.
Written By: Chikkula Pavan Kumar, PharmD
Reviewed By: Pharmacally Editorial Team
Merck and Eisai reported that the Phase 3 LITESPARK-012 trial evaluating new combination regimens for first-line treatment of advanced clear cell renal cell carcinoma (RCC) did not meet its primary endpoints, reinforcing the current standard of care with KEYTRUDA plus LENVIMA.
The study assessed a triplet regimen of KEYTRUDA, LENVIMA, and WELIREG, as well as a doublet regimen of MK-1308A (pembrolizumab plus quavonlimab) with LENVIMA, each compared to KEYTRUDA plus LENVIMA.
At a pre-specified interim analysis, neither experimental regimen showed improvement in progression-free survival or overall survival versus the control arm, while safety profiles remained consistent with known data for the individual agents and combinations.
According to M. Catherine Pietanza, Vice President, Global Clinical Development, Merck Research Laboratories, the trial was intended to determine whether combining therapies with established activity could improve outcomes beyond existing KEYTRUDA-based regimens; although this was not achieved, the findings add to the understanding of advanced RCC and may inform future treatment strategies.
Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai Inc noted that while the outcome was disappointing, it reinforces the role of KEYTRUDA plus LENVIMA as a standard first-line option and contributes to evolving clinical perspectives in RCC management.
The results do not affect other ongoing studies in the LITESPARK program, including the Phase 3 LITESPARK-011 trial evaluating WELIREG with LENVIMA in previously treated patients, for which the U.S. Food and Drug Administration has set a target decision date of October 4, 2026.
LITESPARK-012 enrolled 1,688 patients with advanced clear cell RCC and evaluated outcomes including progression-free survival, overall survival, response rates, and safety.
Renal cell carcinoma accounts for the majority of kidney cancer cases globally, with clear cell RCC being the most common and aggressive subtype, and a substantial proportion of patients diagnosed at an advanced stage.
Reference
https://www.eisai.com/news/2026/news202622.html
About the Writer
Chikkula Pavan Kumar, Pharm.D is a Doctor of Pharmacy with a keen interest in clinical pharmacy, pharmacovigilance, and evidence-based practice. In his words, he is passionate about patient safety and translating complex medical information into clear, research-driven communication.